This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Kakiya, S. Articles by Oiso, Y. Search for Related Content PubMed PubMed Citation Articles by Kakiya, S. Articles by Oiso, Y.

Role of Endogenous Nociceptin in the Regulation of Arginine Vasopressin Release in Conscious Rats

First Department of Internal Medicine (S.K., T.M., H.A., H.Y., Y.M., Y.O.), Department of Clinical Laboratory Medicine (Y.I.), Nagoya University School of Medicine, Showa-ku, Nagoya 466-8550, Japan

Address all correspondence and requests for reprints to: Satoshi Kakiya, First Department of Internal Medicine, Nagoya University School of Medicine, 65 Tsurumai-cho, Showa-ku, Nagoya 466-8550, Japan. E-mail: skakiya{at}med.nagoya-u.ac.jp

The effects of central administration of the opioid-like peptide nociceptin (also known as orphanin FQ) were investigated on the secretion of arginine vasopressin (AVP) in response to dehydration and hyperosmolar or hypovolemic stimulation in conscious rats. Intracerebroventricular (icv) administration of nociceptin suppressed plasma AVP concentration in a dose-dependent manner (0.1–10 µg/rat) in dehydrated rats, and the maximum effect was obtained 10 min after the administration (dehydration with 10 µg/rat nociceptin, 3.11 ± 0.27 pg/ml vs. control, 10.32 ± 0.96 pg/ml). The plasma AVP increase in response to either hyperosmolality [ip injection of hypertonic saline (HS) (600 mosml/kg)] or hypovolemia [ip injection of polyethylene glycol (PEG)] was also significantly blunted when nociceptin was injected icv (HS with 10 µg/rat nociceptin, 1.16 ± 0.09 pg/ml vs. control, 1.82 ± 0.30 pg/ml; PEG with 10 µg/rat nociceptin, 0.91 ± 0.16 pg/ml vs. control, 2.41 ± 0.26 pg/ml). Pretreatment with a selective opioid -receptor antagonist, nor-binaltorphimine (1 µg/rat, icv) or naloxone (2.5 mg/rat, sc injection) did not reverse the inhibitory effects of nociceptin on AVP release. Moreover, when plasma AVP was suppressed by acute water loading, immunoneutralization of endogenous nociceptin by antinociceptin-antiserum icv significantly reversed the suppression (0.57 ± 0.12 pg/ml vs. control, 0.25 ± 0.04 pg/ml). These results suggest that central nociceptin is physiologically involved in the control of AVP release through an inhibitory action.

This article has been cited by other articles:

				R. D. Wainford and D. R. Kapusta Chronic high-NaCl intake prolongs the cardiorenal responses to central N/OFQ and produces regional changes in the endogenous brain NOP receptor system Am J Physiol Regulatory Integrative Comp Physiol, February 1, 2009; 296(2): R280 - R288. [Abstract] [Full Text] [PDF]

				R. D. Wainford, K. Kurtz, and D. R. Kapusta Central G-alpha subunit protein-mediated control of cardiovascular function, urine output, and vasopressin secretion in conscious Sprague-Dawley rats Am J Physiol Regulatory Integrative Comp Physiol, August 1, 2008; 295(2): R535 - R542. [Abstract] [Full Text] [PDF]

				N. Hadrup, J. S. Petersen, S. Windfeld, L. Risom, C. B. Andersen, S. Nielsen, S. Christensen, and T. E. N. Jonassen Differential Down-Regulation of Aquaporin-2 in Rat Kidney Zones by Peripheral Nociceptin/Orphanin FQ Receptor Agonism and Vasopressin Type-2 Receptor Antagonism J. Pharmacol. Exp. Ther., November 1, 2007; 323(2): 516 - 524. [Abstract] [Full Text] [PDF]

				M. A. Burmeister and D. R. Kapusta Centrally Administered Nociceptin/Orphanin FQ (N/OFQ) Evokes Bradycardia, Hypotension, and Diuresis in Mice via Activation of Central N/OFQ Peptide Receptors J. Pharmacol. Exp. Ther., July 1, 2007; 322(1): 324 - 331. [Abstract] [Full Text] [PDF]

				Z. K. Krowicki and D. R. Kapusta Tonic Nociceptinergic Inputs to Neurons in the Hypothalamic Paraventricular Nucleus Contribute to Sympathetic Vasomotor Tone and Water and Electrolyte Homeostasis in Conscious Rats J. Pharmacol. Exp. Ther., April 1, 2006; 317(1): 446 - 453. [Abstract] [Full Text] [PDF]

				D. R. Kapusta, M. A. Burmeister, G. Calo', R. Guerrini, H. B. Gottlieb, and V. A. Kenigs Functional Selectivity of Nociceptin/Orphanin FQ Peptide Receptor Partial Agonists on Cardiovascular and Renal Function J. Pharmacol. Exp. Ther., August 1, 2005; 314(2): 643 - 651. [Abstract] [Full Text] [PDF]

				N. Hadrup, J. S. Petersen, J. Praetorius, E. Meier, M. Graebe, L. Brond, D. Staahltoft, S. Nielsen, S. Christensen, D. R. Kapusta, et al. Opioid receptor-like 1 stimulation in the collecting duct induces aquaresis through vasopressin-independent aquaporin-2 downregulation Am J Physiol Renal Physiol, July 1, 2004; 287(1): F160 - F168. [Abstract] [Full Text] [PDF]

				Y. Sugimura, T. Murase, S. Ishizaki, K. Tachikawa, H. Arima, Y. Miura, T. B. Usdin, and Y. Oiso Centrally Administered Tuberoinfundibular Peptide of 39 Residues Inhibits Arginine Vasopressin Release in Conscious Rats Endocrinology, July 1, 2003; 144(7): 2791 - 2796. [Abstract] [Full Text] [PDF]